1. Diamantopoulos A, Katsanos K. Treating femoropopliteal disease: established and emerging technologies. Semin Intervent Radiol. 2014; 31:345–352. PMID:
25435660.
Article
2. Kasapis C, Gurm HS. Current approach to the diagnosis and treatment of femoral-popliteal arterial disease. A systematic review. Curr Cardiol Rev. 2009; 5:296–311. PMID:
21037847.
Article
3. MacTaggart JN, Phillips NY, Lomneth CS, et al. Three-dimensional bending, torsion and axial compression of the femoropopliteal artery during limb flexion. J Biomech. 2014; 47:2249–2256. PMID:
24856888.
Article
4. Yin WH. Rotational atherectomy: an update. J Geriatr Cardiol. 2013; 10:211–212. PMID:
24133505.
5. Zeller T, Langhoff R, Rocha-Singh KJ, et al. Directional atherectomy followed by a paclitaxel-coated balloon to inhibit restenosis and maintain vessel patency: twelve-month results of the DEFINITIVE AR study. Circ Cardiovasc Interv. 2017; 10:e004848. PMID:
28916599.
Article
6. DeRubertis BD. Interim results of the REALITY trial. In : VINNOVA Symposium (virtual); 2020 May 16; Beijing, China.
7. Dattilo R, Himmelstein SI, Cuff RF. The COMPLIANCE 360° trial: a randomized, prospective, multicenter, pilot study comparing acute and long-term results of orbital atherectomy to balloon angioplasty for calcified femoropopliteal disease. J Invasive Cardiol. 2014; 26:355–360. PMID:
25091093.
8. Stavroulakis K, Schwindt A, Torsello G, et al. Directional atherectomy with antirestenotic therapy vs drug-coated balloon angioplasty alone for common femoral artery atherosclerotic disease. J Endovasc Ther. 2018; 25:92–99. PMID:
29251204.
Article
9. Kansal A, Long CA, Patel MR, Jones WS. Endovascular treatment of femoro-popliteal lesions. Clin Cardiol. 2019; 42:175–183. PMID:
30324655.
Article
10. Cha JJ, Lee JH, Ko YG, et al. Clinical outcomes of atherectomy plus drug-coated balloon versus drug-coated balloon alone in the treatment of femoropopliteal artery disease. Korean Circ J. 2022; 52:123–133.
Article